Clinical Multidisciplinary Hematology & Oncology: The 19th Annual Review - 2025

This course offers attendees a comprehensive update in the diagnosis and management of key diseases in hematology and medical oncology. Presentations provide updates on new data and best practices for physicians and the healthcare team. The format for this activity is didactic presentations followed by Q&A sessions. In person and virtual attendance will be offered. Continuing medical education credits will be offered for physicians, APPs, pharmacists, and nurses. Learning Objectives Upon completion of this activity, participants should be able to: - Identify optimal treatment selection for castrate-resistant prostate cancer patients. - Identify targeted therapy for IDH 1 and 2 mutant grade 2 glioma patients. - Review the first-line treatment options for metastatic colorectal cancer patients. - Recognize different ways to manage stage III lung cancer. - Identify the role of immunotherapy in the treatment of triple-negative breast cancer patients. - Review the indications for bispecific T cell engagers (bispecific antibodies) in lymphoma. - Review the potential toxicities and toxicity management for multiple myeloma patients receiving CART or bispecific antibodies. - Describe the application of newly approved drugs for classical hematology. - Identify treatment strategies for Richter’s transformation.